Effects of Asymmetries on Binaural-Hearing Abilities Across the Lifespan
Launched by UNIVERSITY OF MARYLAND, COLLEGE PARK · Apr 23, 2025
Trial Information
Current as of July 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (18-80 years)
- • No hearing asymmetry between ears (≤10 dB at any frequency) or, hearing asymmetry between ears \>10 dB
- • Native English speakers
- • Primarily use oral language
- • Sufficient corrected or uncorrected visual acuity (20/50 or better) to read large-font text
- Exclusion Criteria:
- • Acoustic tone-detection threshold \>50 dB HL at any octave frequency (250-4000 Hz) in either ear (i.e., more than a moderate hearing loss)
- • History of neurological disorders (e.g., stroke, Parkinson's disease) determined by self-report
- • History of post-traumatic stress disorder or traumatic brain injury determined by self-report
- • Possibility of acoustic neuroma, hearing asymmetry (\>10 dB at three consecutive audiometric threshold frequencies)
- • Montreal Cognitive Assessment (MoCA) score \<22/30
- • No oral language use
- • Cochlear implant user
- • Conductive hearing loss
About University Of Maryland, College Park
The University of Maryland, College Park, is a leading research institution dedicated to advancing knowledge and innovation in various fields, including health and medicine. As a prominent clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and commitment to rigorous scientific inquiry to facilitate impactful clinical research. The institution fosters collaborations among faculty, healthcare professionals, and industry partners to enhance patient care and drive advancements in medical science, ensuring compliance with ethical standards and regulatory requirements throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
College Park, Maryland, United States
Patients applied
Trial Officials
Matthew J. Goupell, PhD
Principal Investigator
University of Maryland, College Park
Michael P. Cummings, PhD
Study Director
University of Maryland, College Park
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported